iGPS introduces pallet rental service
ORLANDO, Fla. Intelligent Global Pooling Systems has developed a pallet rental service providing 100% recyclable all-plastic pallets with embedded radio frequency identification tags.
iGPS bios will offer premier hygiene and secure pallets, ideal for those in the pharmaceutical and life science industries, as well as savings for a company’s bottom line, iGPS said. Each pallet is individually washed and sanitized at an iGPS facility, then immediately enclosed in protective wrapping to maintain its hygienic condition, the company added.
"The pharmaceutical and life sciences industries are so critical to our economy and our well-being. They deserve a shipping platform that is commensurate with their importance and consistent with the superior hygiene standards they exemplify," said Bob Moore, iGPS chairman and CEO. "We are proud to offer iGPS bios, which is a quantum leap beyond other platforms available today."
Big Y finalizing purchase of Conn.-based A&P stores
SPRINGFIELD, Mass. Big Y reportedly is closing its deal to acquire seven A&P stores in northern Connecticut.
The Springfield, Mass.-based retailer said the sale will be completed on Nov. 1, according to the Boston Herald. Big Y owns stores in Massachusetts and Connecticut and has served these markets for nearly 75 years.
As previously reported by Drug Store News, grocer A&P announced in September an agreement with Big Y to sell the stores as part of its turnaround strategy.
“We continue to evaluate our operating footprint and its alignment with our turnaround strategy. These seven stores were clearly outside of our core markets, and their sale was necessary,” Sam Martin, president and CEO of A&P, stated at the time.
NeurogesX seeks expanded approval for Qutenza
SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.
NeurogesX announced Monday that it would seek Food and Drug Administration approval for the drug Qutenza (capsaicin) as a treatment for HIV-associated neuropathy, also called HIV-AN or HIV-distal sensory polyneuropathy, in the first half of 2011. The drug, a patch, already is approved for post-herpetic neuralgia. HIV-AN results from injury to sensory neurons by HIV virus proteins, the body’s immune response to the virus and some drugs used to treat it.
“As a company, we are focused on addressing unmet medical needs in pain and have made significant progress toward this goal with the U.S. launch of Qutenza,” NeurogesX president and CEO Anthony DiTonno said. “Our decision to submit a supplemental [application] to address the HIV-AN patient population is important as there are currently no FDA-approved treatments for HIV-AN.”